These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27486203)

  • 1. Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.
    Usmani S; Ahmadi T; Ng Y; Lam A; Desai A; Potluri R; Mehra M
    Oncologist; 2016 Nov; 21(11):1355-1361. PubMed ID: 27486203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
    Usmani SZ; Diels J; Ito T; Mehra M; Khan I; Lam A
    Am J Hematol; 2017 Aug; 92(8):E146-E152. PubMed ID: 28474745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy.
    Brechbühl S; Bacher U; Jeker B; Pabst T
    Mediterr J Hematol Infect Dis; 2021; 13(1):e2021012. PubMed ID: 33489051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
    Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
    Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
    Usmani SZ; Weiss BM; Plesner T; Bahlis NJ; Belch A; Lonial S; Lokhorst HM; Voorhees PM; Richardson PG; Chari A; Sasser AK; Axel A; Feng H; Uhlar CM; Wang J; Khan I; Ahmadi T; Nahi H
    Blood; 2016 Jul; 128(1):37-44. PubMed ID: 27216216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study.
    Wang PF; Yee CW; Gorsh B; Zichlin ML; Paka P; Bhak RH; Boytsov N; Khanal A; Noman A; DerSarkissian M; Ferrante S; Duh MS
    Leuk Lymphoma; 2023 Feb; 64(2):398-406. PubMed ID: 36408998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
    Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
    Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
    Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
    Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA.
    Hari P; Blazer M; Raju A; Farrelly E; Labotka R; Skacel T; Romanus D
    Expert Rev Hematol; 2019 Jan; 12(1):71-79. PubMed ID: 30513016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure.
    Zamanillo I; Medina de Alba L; Gil R; de la Puerta R; Alonso R; Jimenez-Ubieto A; Cedena MT; Calbacho M; Ayala R; Martinez-Lopez J
    Life (Basel); 2023 Aug; 13(9):. PubMed ID: 37763245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.
    Kumar SK; Dimopoulos MA; Kastritis E; Terpos E; Nahi H; Goldschmidt H; Hillengass J; Leleu X; Beksac M; Alsina M; Oriol A; Cavo M; Ocio EM; Mateos MV; O'Donnell EK; Vij R; Lokhorst HM; van de Donk NWCJ; Min C; Mark T; Turesson I; Hansson M; Ludwig H; Jagannath S; Delforge M; Kyriakou C; Hari P; Mellqvist U; Usmani SZ; Dytfeld D; Badros AZ; Moreau P; Kim K; Otero PR; Lee JH; Shustik C; Waller D; Chng WJ; Ozaki S; Lee JJ; de la Rubia J; Eom HS; Rosinol L; Lahuerta JJ; Sureda A; Kim JS; Durie BGM
    Leukemia; 2017 Nov; 31(11):2443-2448. PubMed ID: 28620163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study.
    Mateos MV; Weisel K; Diels J; Arribas A; Tamayo M; Schecter JM; Roccia T; Haddad I; Pacaud L; Moreau P
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):224-231.e2. PubMed ID: 38212206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
    Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
    Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.
    Mateos MV; Weisel K; De Stefano V; Goldschmidt H; Delforge M; Mohty M; Cavo M; Vij R; Lindsey-Hill J; Dytfeld D; Angelucci E; Perrot A; Benjamin R; van de Donk NWCJ; Ocio EM; Scheid C; Gay F; Roeloffzen W; Rodriguez-Otero P; Broijl A; Potamianou A; Sakabedoyan C; Semerjian M; Keim S; Strulev V; Schecter JM; Vogel M; Wapenaar R; Nesheiwat T; San-Miguel J; Sonneveld P; Einsele H; Moreau P
    Leukemia; 2022 May; 36(5):1371-1376. PubMed ID: 35332278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
    Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
    Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
    Talbot A; Bobin A; Tabone L; Lambert J; Boccaccio C; Deal C; Petillon MO; Allangba O; Agape P; Arnautou P; Belkhir R; Cailleres S; Chaoui D; Chrétien ML; Decaux O; Schulmann S; Frenzel L; Gastaud L; Huart A; Hulin C; Karlin L; Laribi K; Le Calloch R; Lenain P; Macro M; Manier S; Montes L; Moreau S; Moreau P; Morel V; Norwood J; Piocelle FO; Perrot A; Pica GM; Rey P; Schmitt A; Stoppa AM; Tiab M; Touzeau C; Vidal V; Vignon M; Vincent L; Van De Wyngaert Z; Zarnitsky C; Kerbouche N; Paka P; Leleu X; Arnulf B; Avet-Loiseau H; Du Myélome IIF
    Haematologica; 2023 Oct; 108(10):2774-2782. PubMed ID: 37078253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data.
    Braunlin M; Belani R; Buchanan J; Wheeling T; Kim C
    Leuk Lymphoma; 2021 Feb; 62(2):377-386. PubMed ID: 33026271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.
    Jagannath S; Roy A; Kish J; Lunacsek O; Globe D; Eaddy M; Kuriakose ET; Willey J; Butler-Bird S; Siegel D
    Expert Rev Hematol; 2016 Jul; 9(7):707-17. PubMed ID: 27291638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management and outcome of 500 multiple myeloma patients treated for first relapse outside clinical studies.
    Avivi I; Yekutiel N; Shragai T; Cohen YC; Grunspan M; Rivlin N; Frankel N; Cohen R; Weil C; Chodick G
    Ann Hematol; 2023 Nov; 102(11):3075-3081. PubMed ID: 37646848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.